


Form PTO-1595 (Rev. 08/05)
OMB No. 0651-0027 (exp. 5/30/2008)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies): Baxter Healthcare S.A. and Baxter International, Inc. Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No	2. Name and address of receiving party(ies) Name: <u>ZIOPHARM Oncology, Inc.</u> Internal Address: _____ Street Address: _____ Suite 300, Flagship Wharf 197 Eighth Street City: <u>Charlestown</u> State: <u>Massachusetts</u> Country: <u>U.S.A.</u> Zip: <u>02129</u> Additional name(s) & address(es) attached? ☐ Yes ☒ No
3. Nature of conveyance/Execution Date(s): Execution Date(s): <u>July 25, 2007</u> ☒ Assignment ☐ Merger ☐ Change of Name ☐ Security Agreement ☐ Joint Research Agreement ☐ Government Interest Assignment ☐ Executive Order 9424, Confirmatory License ☐ Other _____	4. Application or patent number(s): A. Patent Application No.(s) <u>10/686809</u> <u>11/151459</u> Additional numbers attached? ☐ Yes ☒ No B. Patent No.(s) <u>6008231</u> <u>6919344</u> <u>6344467</u> <u>6693119</u> This document is being filed together with a new application. ☐ Yes ☒ No
5. Name and address to whom correspondence concerning document should be mailed: Name: <u>Matthew P. Vincent, J.D., Ph.D.</u> <u>FISH & NEAVE IP GROUP, ROPES & GRAY</u> <u>LLP</u> Internal Address: Atty. Dkt.: <u>ZIPH-GIP-001</u> Street Address: <u>One International Place</u> City: <u>Boston</u> State: <u>MA</u> Zip: <u>02110-2624</u> Phone Number: <u>(617) 951-7739</u> Fax Number: <u>(617) 951-7050</u> Email Address: <u>MVincent@ropesgray.com</u>	6. Total number of applications and patents involved: 7. Total fee (37 CFR 1.21(h) & 3.41) \$ <u>240.00</u> ☐ Authorized to be charged by credit card ☒ Authorized to be charged to deposit account ☐ Enclosed ☐ None required (government interest not affecting title)
9. Signature:  _____ Signature <u>Maya Escobar -- 56,346</u> Name of Person Signing	8. Payment Information a. Credit Card Last 4 Numbers _____ Expiration Date _____ b. Deposit Account Number <u>18-1945</u> Authorized User Name <u>Matthew P. Vincent</u> August 20, 2007 Date Total number of pages including cover sheet, attachments, and documents: 7

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-0140, on the date shown below

Dated: 8/20/07 Signature: Valerie J. Sarosky (Valerie J. Sarosky)

CH \$240.00 181945 10686809

REVISED ASSIGNMENT

This Revised Assignment is dated and delivered as of this 25th day of July, 2007, with a retroactive effective date of November 3, 2006, by and between Baxter Healthcare S.A. and Baxter International, Inc. (collectively, the "Sellers"), and Ziopharm Oncology, Inc. (the "Buyer").

WITNESSETH:

WHEREAS, Buyer and Sellers are parties to an Asset Purchase Agreement dated as of November 3, 2006 (the "Purchase Agreement") which provides, among other things, for the transfer by Sellers of the Patents, as that term is defined in the Purchase Agreement;


WHEREAS, Buyer and Sellers had previously executed an Assignment on or about November 3, 2006 ("Original Assignment") and it was later discovered that the Original Assignment erroneously did not include a complete list of patents for case number 5878;

NOW, THEREFORE TO WHOM IT MAY CONCERN, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, subject to the terms of the Purchase Agreement Sellers hereby sell, assign, transfer, and set over, to Buyer, its successors, legal representatives and assigns, its entire right, title, and interest in the patents and patent applications listed in Schedule I, and in and to all extensions, renewals, and reissues thereof.

In Witness Whereof, Sellers have caused this Assignment to be signed by its duly authorized officer


SELLERS:

BAXTER HEALTHCARE S.A.

By: 
Name: Joseph Reagon
Title: Assistant General Counsel


SELLERS:

BAXTER INTERNATIONAL INC.

By: 
Name: David P. Schant
Title: Corporate VP & Corp Sec

Agreed to and Accepted:**BUYER:**

ZIOPHARMONCOLOGY, INC.

By: 
Name: RICHARD E BAGLEY
Title: PRESIDENT, COO

SCHEDULE I

Patents

Case Number: 6052-*Title:* Pharmaceutical Dosage Form for Oral Administration of a Hardly Soluble Active Ingredient, a Process for its Preparation and a Kit

Country	Case Type	Status	Appl. Number	Filing Date	Patent N.	Issue Date	Exp. Date
Germany	ORD	Published	1004031538.8	29-Jun-2004			
Patent Cooperation Treaty	ORD	Published	EP2005/006991	29-Jun-2005			
United States of America	PRO	Closed	60/583815	29-Jun-2004			
United States of America	ORD	Published	11/169407	29-Jun-2005			

Case Number: 5838-*Title:* Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

Country	Case Type	Status	Application Number	Filing Date	Patent No.	Issue Date	Exp. Date
Algeria	PCT	Granted	020076	26-Sep-2000	3196	20-Feb-2005	26-Sep-2020
Argentina	ORD	Pending	P000105105	28-Sep-2000			
Australia	PCT	Granted	77829/00	26-Sep-2000	783436	09-Feb-2006	26-Sep-2020
Belarus	PCT	Pending	20020358	26-Sep-2000			
Brazil	PCT	Pending	PI 0014378-2	26-Sep-2000			
Bulgaria	PCT	Pending	106639	26-Sep-2000			
Canada	PCT	Pending	2386069	26-Sep-2000			
China (Peoples Republic)	PCT	Pending	00813449.9	26-Sep-2000			
Croatia	PCT	Pending	P20020369A	26-Sep-2000			
Czech Republic	PCT	Pending	PV 2002-1005	26-Sep-2000			
Estonia	PCT	Published	P200200169	26-Sep-2000			
European Patent Convention	PCT	Published	00967789.9	26-Sep-2000			
Georgia	PCT	Granted	2000004745	26-Sep-2000	3250	25-Jun-2004	26-Sep-2020
Germany	POA	Published	19946301.8	28-Sep-1999			
Hong Kong	ORD	Pending	03101178.9	26-Sep-2000			
Hungary	PCT	Published	P0202788	26-Sep-2000			
Iceland	PCT	Pending	6319	26-Sep-2000			
India	PCT	Pending	2002/00399	26-Sep-2000			
Indonesia	PCT	Pending	W-00200200750	26-Sep-2000			
Israel	PCT	Pending	148670	26-Sep-2000			
Japan	PCT	Pending	2001-526166	26-Sep-2000			
Kazakstan	PCT	Granted	2002/1517.1	26-Sep-2000	15792	04-Apr-2005	26-Sep-2020
Korea, Republic of	PCT	Pending	2002-7003937	26-Sep-2000			
Mexico	PCT	Granted	2002/002824	26-Sep-2000	231730	01-Nov-2005	26-Sep-2020
New Zealand	PCT	Granted	517988	26-Sep-2000	517988	10-Feb-2005	26-Sep-2020
Norway	PCT	Pending	20021367	26-Sep-2000			
Patent Cooperation Treaty	ORD	Closed	EP00/09390	26-Sep-2000			
Poland	PCT	Pending	P 364811	26-Sep-2000			
Russian Federation	PCT	Pending	2002111866	26-Sep-2000			
Serbia and Montenegro	PCT	Pending	P-227/02	26-Sep-2000			
Singapore	PCT	Granted	200201907-3	26-Sep-2000	88180	28-Feb-2005	26-Sep-2020
Slovakia	PCT	Pending	PV 0407-2002	26-Sep-2000			
South Africa	PCT	Granted	2002/2556	26-Sep-2000	2002/2556	27-Aug-2003	26-Sep-2020
Taiwan	ORD	Pending	89119680	22-Sep-2000			
Turkey	PCT	Pending	2002/00815	26-Sep-2000			

126407_1

Ukraine	PCT	Granted	2002043433	26-Sep-2000	75872	15-Jun-2006	26-Sep-2020
United States of America	CPA	Granted	09/492531	27-Jan-2000	6693119	17-Feb-2004	02-Apr-2019
United States of America	CON	Published	10/686809	17-Oct-2003			

Case Number: 5878-

Title: Indolyl-3-glyoxylic acid derivatives with antitumoral activity

Country	Case Type	Status	App No.	Filing Date	Patent No.	Issue Date	Exp Date
Argentina	ORD	Pending	P990101501	31-Mar-1999			
Australia	PCT	Pending	29349/99	22-Mar-1999	768510		
Austria	EPC	Granted	99910372.4	22-Mar-1999	E304352	14-Sep-2005	22-Mar-2019
Belarus	PCT	Granted	20000998	22-Mar-1999	8036	20-Jan-2006	22-Mar-2019
Belgium	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Brazil	PCT	Pending	PI 9909902-0	22-Mar-1999			
Bulgaria	PCT	Granted	104849	22-Mar-1999	64838	12-Apr-2006	22-Mar-2019
Canada	PCT	Pending	2326833	22-Mar-1999			
Chile	ORD	Pending	611-99	31-Mar-1999			
China (Peoples Republic)	PCT	Granted	99805923.4	22-Mar-1999	99805923.4	02-Jan-2004	22-Mar-2019
Colombia	ORD	Pending	99019143	30-Mar-1999			
Croatia	PCT	Pending	P20000643A	22-Mar-1999			
Czech Republic	PCT	Pending	PV 2000-3483	22-Mar-1999			
Denmark	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Estonia	PCT	Granted	P200000581	22-Mar-1999	04354	15-Oct-2004	
European Patent Convention	PCT	Closed	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Finland	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
France	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Georgia	PCT	Granted	1999004136	22-Mar-1999	2967	27-Mar-2003	22-Mar-2019
Germany	EPC	Granted	99910372.4	22-Mar-1999	59912562.4	14-Sep-2005	22-Mar-2019
GermanyDE0	ORD	Granted	19814838.0	02-Apr-1998	19814838	18-Jan-2001	02-Apr-2018
Greece	EPC	Granted	99910372.4	22-Mar-1999	3055754	14-Sep-2005	22-Mar-2019
Hong Kong	ORD	Granted	01107405.3	24-Oct-2001	HK1036408	18-Feb-2005	24-Oct-2021
Hungary	PCT	Pending	P0101530	22-Mar-1999			
Iceland	PCT	Pending	5635	22-Mar-1999			
India	PCT	Pending	2000/00323	22-Mar-1999			
Indonesia	PCT	Granted	W-20001988	22-Mar-1999	ID0014770	07-Dec-2004	22-Mar-2019
Ireland	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Israel	PCT	Pending	138737	22-Mar-1999			
Italy	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Japan	PCT	Pending	2000-541995	22-Mar-1999			
Kazakstan	PCT	Granted	2000/1574.1	22-Mar-1999	12064	15-Dec-2005	22-Mar-2019
Korea, Republic of	PCT	Granted	2000-7010934	22-Mar-1999	583545	19-May-2006	22-Mar-2019
Latvia	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Liechtenstein	EPC	Granted	99910372.4	22-Mar-1999	EP1041420	14-Sep-2005	22-Mar-2019
Lithuania	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Luxembourg	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Macedonia	EPC	Granted	99910372.4	22-Mar-1999	P2005/394	14-Sep-2005	22-Mar-2019
Mexico	PCT	Granted	2000/009646	22-Mar-1999	230549	14-Sep-2005	22-Mar-2019
Netherlands	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019

New Zealand	PCT	Granted	507084	22-Mar-1999	507084	09-Feb-2004	22-Mar-2019
Norway	PCT	Pending	20004916	22-Mar-1999			
Patent Cooperation Treaty	ORD	Closed	EP99/01918	22-Mar-1999			
Poland	PCT	Pending	P343525	22-Mar-1999			
Portugal	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Romania	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Russian Federation	PCT	Granted	2000128035	22-Mar-1999	2262339	20-Oct-2005	22-Mar-2019
Serbia and Montenegro	PCT	Pending	P-593/2000	22-Mar-1999			
Singapore	PCT	Granted	200005600-2	22-Mar-1999	76284	28-Apr-2006	22-Mar-2019
Slovakia	PCT	Pending	PV1430-2000	22-Mar-1999			
Slovenia	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
South Africa	PCT	Granted	2000/6150	22-Mar-1999	2000/6150	28-Feb-2001	22-Mar-2019
Spain	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Sweden	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Switzerland	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
Taiwan	ORD	Granted	88104599	23-Mar-1999	230608	11-Apr-2005	22-Mar-2019
Turkey	PCT	Granted	2000/02853	22-Mar-1999	TR200002853	21-Jun-2004	22-Mar-2019
Ukraine	PCT	Granted	2000116192	22-Mar-1999	70942	15-Nov-2004	22-Mar-2019
United Kingdom	EPC	Granted	99910372.4	22-Mar-1999	EP1071420	14-Sep-2005	22-Mar-2019
United States of America	ORD	Granted	09/285058	02-Apr-1999	6232327	15-May-2001	02-Apr-2019
United States of America	CON	Abandoned	09/810604	19-Mar-2001			
United States of America	CON	Published	10/309204	04-Dec-2002			

Case Number: 6152-

Title: N-substituted indole-3 glyoxylamides having antiasthmatic antiallergic and immunosuppressant/immunomodulating action

Country	Case Type	Status	Appl. No.	Filing Date	Patent No.	Issue Date	Exp. Date
Argentina	ORD	Pending	P970104064	05-Sep-1997			
Australia	PCT	Granted	40158/97	16-Aug-1997	726521	22-Feb-2001	16-Aug-2017
Brazil	PCT	Pending	PI 9712808-2	16-Aug-1997			
Canada	ORD	Granted	2215013	04-Sep-1997	2215013	05-Mar-2002	04-Sep-2017
China (Peoples Republic)	PCT	Published	97197128.5	16-Aug-1997			
China (Peoples Republic)	DIV	Published	02132061.6	16-Aug-1997			
Czech Republic	PCT	Pending	PV 1999-616	16-Aug-1997			
European Patent Convention	PCT	Granted	97937586.2	16-Aug-1997	EP0931063	18-Oct-2006	16-Aug-2017
Germany	ORD	Published	19636150.8	06-Sep-1996			
Hong Kong	ORD	Published	00100629.9	04-Apr-1997			
Hong Kong	ORD	Pending	04107115.1	04-Apr-1997			
Hungary	PCT	Pending	P 9903741	16-Aug-1997			
India	ORD	Pending	1587/CAL/97	28-Aug-1997			
India	DIV	Pending	700/CAL/99	28-Aug-1997			
Israel	PCT	Granted	127798	16-Aug-1997	127798	02-Nov-2003	16-Aug-2017
Japan	PCT	Granted	1998-512167	16-Aug-1997	3296437	12-Apr-2002	16-Aug-2017
Korea, Republic of	PCT	Granted	1999-7001909	16-Aug-1997	516321	14-Sep-2005	16-Aug-2017
Mexico	PCT	Granted	992195	16-Aug-1997	209955	26-Aug-2002	16-Aug-2017
Mexico	DIV	Pending	2002/008227	16-Aug-1997			
New Zealand	PCT	Granted	334476	16-Aug-1997	334476	07-Sep-2000	16-Aug-2017
Norway	PCT	Granted	19991071	16-Aug-1997	314725	12-May-2003	16-Aug-2017
Norway	DIV	Abandoned	20030481	16-Aug-1997			
Patent Cooperation Treaty	ORD	Closed	EP97/04474	16-Aug-1997			
Russian Federation	PCT	Granted	99106782	16-Aug-1997	2237661	10-Oct-2004	16-Aug-2017

Singapore	PCT	Granted	9806358-9	16-Aug-1997	61073	22-May-2001	16-Aug-2017
Slovakia	PCT	Pending	PV 0271-99	16-Aug-1997			
South Africa	ORD	Granted	97/7475	20-Aug-1997	97/7475	29-Apr-1998	20-Aug-2017
Taiwan	ORD	Granted	86112985	06-Sep-1997	185381	13-Jan-2004	06-Sep-2017
Turkey	PCT	Granted	1999/00469	16-Aug-1997	199900469	21-Aug-2001	16-Aug-2017
Ukraine	PCT	Granted	99041907	16-Aug-1997	60312	15-Oct-2003	16-Aug-2017
United States of America	ORD	Granted	08/925326	08-Sep-1997	6008231	28-Dec-1999	08-Sep-2017
United States of America	DIV	Granted	09/409263	30-Sep-1999	6344467	05-Feb-2002	08-Sep-2017
United States of America	DIV	Abandoned	10/058836	30-Jan-2002			
United States of America	CON	Granted	10/402931	01-Apr-2003	6919344	19-Jul-2005	17-Oct-2017

Case Number: 6211-

Title: Pharmaceutical formulation of the tubulin inhibitor Indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof

Country	Case Type	Status	Appl. No	Filing Date	Patent N.	Issue Date	Exp. Date
Patent Cooperation Treaty	ORD	Pending	EP2006/005423	07-Jun-2006			
United States of America	ORD	Pending	11/151459	14-Jun-2005			

FAX TRANSMISSION

DATE: August 20, 2007

PTO IDENTIFIER: Application Number: 10/686,809 et al.

Inventor:

MESSAGE TO: USPTO PTAS System

FAX NUMBER: (571) 273-0140

FROM: FISH & NEAVE IP GROUP, ROPES & GRAY LLP

Maya Escobar, Ph.D.

PHONE: (617) 951-7173

Attorney Dkt. #: ZIPH-GIP-001

PAGES (Including Cover Sheet): 9

CONTENTS: Assignment (6 pages)
Recordation Form Cover Sheet (1page)
Charge \$240.00 to deposit account 18-1945
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7173 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

FISH & NEAVE IP GROUP, ROPES & GRAY LLP
One International Place, Boston, Massachusetts 02110
Telephone: (617) 951-7000 **Facsimile:** (617) 951-7050

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Application No. (if known):

Attorney Docket No.: ZIPH-GIP-001

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, facsimile no. (571) 273-0140.

on August 20, 2007
Date


Signature

Valerie J. Sarosky

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 854-2087

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Assignment (9 pages)
Charge \$240.00 to deposit account 18-1945